REMARKS

I. Amendments

By this amendment, claims 16 and 18 have been amended and claims 10-12 and 27 have been cancelled. This amendment adds no new matter to the specification. Support for this amendment is found in the specification and claims as originally filed.

No amendment of inventorship is necessitated by this amendment.

II. Discussion of the Rejection under 35 U.S.C. Sec. 112, First Paragraph

Claims 9-12, 16, 18, 24, 27 and 28 have been rejected under 35 U.S.C. Sec. 112, first paragraph as allegedly lacking enablement. Applicants respectfully traverse the rejection.

By this amendment, independent claims 16 and 18 have been amended as suggested by the Examiner on page 5 of the Office Action to overcome the rejection, with concomitant cancellation of claims 10-12 and 27.

Claim 24 depends upon claim 16 and claims 9 and 28 depend upon claim 18. Applicants assert that the more specific dependent claims are also adequately enabled by virtue of the modifications of their related independent claims.

Therefore Applicants respectfully request withdrawal of the Sec. 112, first paragraph rejection.

III. Conclusion

Reconsideration and allowance of the claims as amended is respectfully requested. Should the Examiner believe that a conference with Applicants' attorney would advance prosecution of this application, he is respectfully requested to call Applicants' attorney at (847) 383-3391.

Respectfully submitted,

Dated: December 3, 2005

(847) 383-3391 (847) 383-3372

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department 475 Half Day Road Lincolnshire, IL 60069 USA Elaine M Ramach Dh D. Dag No.

Elaine M. Ramesh, Ph.D., Reg. No. 43,032

Mark Chao, Ph.D., Reg. No. 37,293

Attorney for Applicants Customer No. 23115

Certificate of Mailing under 37 CFR 1.10

Express Mail Label No. EV 617428214 US

Printed Name: Gail L. Winokur